Metapristone (RU486 metabolite) suppresses NSCLC by targeting EGFR-mediated PI3K/AKT pathway.
Shao J, Zheng G, Chen H, Liu J, Xu A, Chen F, Li T, Lu Y, Xu J, Zheng N, Jia L.
Shao J, et al. Among authors: zheng g, zheng n.
Oncotarget. 2017 Jun 27;8(45):78351-78364. doi: 10.18632/oncotarget.18640. eCollection 2017 Oct 3.
Oncotarget. 2017.
PMID: 29108234
Free PMC article.